Chronic Myeloid Leukemia | Topics

Results from the phase 3 ASCEMBL trial led to the approval of asciminib by the European Commission for patients with Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase.

Findings from the phase 3 ASCEMBL trial indicated that asciminib as a treatment for chronic myelogenous leukemia in chronic phase could represent a new standard of care.

Improvement in major molecular response rate and depth of response coupled with a favorable safety profile were noted with asciminib vs bosutinib in patients with chronic-phase chronic myeloid leukemia.

In a population of patients with chronic myeloid leukemia with resistant disease experienced promising activity following treatment with ponatinib regardless of T315I mutation status.

The FDA granted accelerated approval to asciminib for the treatment of patients with Philadelphia chromosome–positive chronic myeloid leukemia for 2 indications.

The FDA has granted breakthrough therapy designation to asciminib for the treatment of adult patients with Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase who have been previously treated with 2 or more tyrosine kinase inhibitors; or who harbor the T315I mutation.

The FDA approved the supplemental new drug application for ponatinib (Iclusig) to treat patients with chronic-phase chronic myeloid leukemia (CML) with resistance or intolerance to at least two prior kinase inhibitors.

Researchers found that long-term treatment-free remission was not impaired by low-dose TKI regimens for patients with chronic myeloid leukemia.

The study is evaluating asciminib in adult patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who were previously treated with 2 or more tyrosine-kinase inhibitors.

The FDA granted orphan drug designation to Ascentage Pharma’s HQP1351 for the treatment of chronic myeloid leukemia.